Safety and efficacy of Rezūm water vapour energy therapy in BPH patients receiving antithrombotic therapy: A Japanese single‐centre experience
WAVE can be safely performed with continued antithrombotic therapy. Whereas Grade ≥Ib hematuria occurred in 25% of antiplatelet/anticoagulant users (vs. 5% without), 75% had no significant bleeding, and all complications were managed conservatively without transfusion. The OU-mCD provides precise complication stratification. These findings suggest outpatient procedures may be feasible with appropriate patient selection.
Authors
- Haruki Kaku
- Tatsushi Kawada (ORCID: https://orcid.org/0000-0002-8369-9712)
- Satoshi Katayama (ORCID: https://orcid.org/0000-0002-8377-2457)
- Tomoaki Yamanoi (ORCID: https://orcid.org/0009-0006-9821-9407)
- Yasuhiro Katayama (ORCID: https://orcid.org/0000-0003-1218-9130)
- Takehiro Iwata
- K. Yoshinaga
- Motoo Araki
- Takatoshi Moriwake
- Takuya Sadahira
- Ichiro Tsuboi
- Yusuke Tominaga
- Shingo Nishimura
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
Publication Details
- Journal
- BJUI Compass
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/bco2.70170
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00